297 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
2 May 24
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
8:11am
approval for its product candidates, including vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling
8-K
ALNY
Alnylam Pharmaceuticals Inc
4 Mar 24
Departure of Directors or Certain Officers
4:33pm
services, and (5) reimbursement for up to $15,000 of legal fees.
The Letter Agreement also provides for a one-year consulting arrangement with Ms
8-K
EX-10.1
ALNY
Alnylam Pharmaceuticals Inc
4 Mar 24
Departure of Directors or Certain Officers
4:33pm
as of the end of your Consulting Period and related agreements entered
into with you under the Company’s equity plans; (c) your right to reimbursement
8-K
EX-99.1
5xpq6rt1o9mytaj7z
15 Feb 24
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
0kdc5lnza24d4lwido
8 Jan 24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
7:00am
8-K
EX-99.1
gcyzdd7p9a95p6
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
piyu8ip i2en
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
8-K
EX-99.1
288j 0g7zs
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
EX-99.1
o0yuud97d679qzodom
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
2isyv544uy
30 Jun 23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
9:03am
8-K
EX-99.1
r5fuyfft
4 May 23
Results of Operations and Financial Condition
8:10am